TET2 and neoplasm: In this study, we revealed DNA damage, TET2 upregulation, demethylation, and re-expression of tumor suppressors on the underlying mechanism of DNMTi anticancer activity and resistance, particularly in the context of a lower dose (0.5 μM) of DNMTi, in the presence and absence of the DNMT1 gene (Figure 4).